Trial Profile
Intratumoral Injection of SD-101, an Immunostimulatory CpG, in Combination With Ibrutinib and Local Radiation in Relapsed or Refractory Low-Grade Follicular Lymphoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 24 Nov 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Nelitolimod (Primary)
- Indications B-cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 20 Nov 2023 Status changed from active, no longer recruiting to completed.
- 13 Dec 2022 clinical and immunological Results(n=20) presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 13 Jun 2022 Planned End Date changed from 1 Nov 2021 to 2 Nov 2023.